Surveillance of antiviral resistance markers in Argentina: detection of E119V neuraminidase mutation in a post-treatment immunocompromised patient by Pontoriero, Andrea et al.
Mem Inst Oswaldo Cruz, Rio de Janeiro: 1-5, 2016 1
online | memorias.ioc.fiocruz.br
Surveillance of antiviral resistance markers in Argentina:  
detection of E119V neuraminidase mutation in a  
post-treatment immunocompromised patient
Andrea Pontoriero1, Martín Avaro1, Estefania Benedetti1, Mara Russo1,  
Andrea Czech1, Natalia Periolo1, Ana Campos1, Ana Zamora2, Elsa Baumeister1/+
1National Influenza Centre PAHO/WHO, National Reference Laboratory, Respiratory Viral Diseases Service, Department of Virology,  
National Institute of Infectious Diseases, National Agency of Laboratories and Institutes of Health Dr Carlos G Malbrán, Ciudad de Buenos Aires, 
Buenos Aires, Argentina 2University of Tucuman, School of Pharmacy and Biochemistry, Microbiology Institute, Tucuman, Argentina
Although vaccines are the best means of protection against influenza, neuraminidase inhibitors are currently the 
main antiviral treatment available to control severe influenza cases. One of the most frequent substitutions in the neur-
aminidase (NA) protein of influenza A(H3N2) viruses during or soon after oseltamivir administration is E119V muta-
tion. We describe the emergence of a mixed viral population with the E119E/V mutation in the NA protein sequence in 
a post-treatment influenza sample collected from an immunocompromised patient in Argentina. This substitution was 
identified by a real-time reverse transcriptase polymerase chain reaction (RT-PCR) protocol and was confirmed by di-
rect Sanger sequencing of the original sample. In 2014, out of 1140 influenza samples received at the National Influenza 
Centre, 888 samples (78%) were A(H3N2) strains, 244 (21.3%) were type B strains, and 8 (0.7%) were A(H1N1)pdm09 
strains. Out of 888 A(H3N2) samples, 842 were tested for the E119V substitution by quantitative RT-PCR: 841 A(H3N2) 
samples had the wild-type E119 genotype and in one sample, a mixture of viral E119/ V119 subpopulations was detected. 
Influenza virus surveillance and antiviral resistance studies can lead to better decisions in health policies and help in 
medical treatment planning, especially for severe cases and immunocompromised patients.
Key words: influenza resistance - Argentina - E119V substitution - surveillance
doi: 10.1590/0074-02760160262
Financial support: FOCANLIS 2011 (grant given by the National 
Agency of Laboratories and Institutes of Health Dr Carlos G 
Malbrán), National Agency of Scientific Research, Technology and 
Innovation of Argentina (grant PICT 000422008).
+ Corresponding author: ebaumeister@anlis.gov.ar
Received 13 June 2016
Accepted 2 September 2016
Influenza virus is a major human pathogen associated 
with high morbidity and mortality both in temperate and 
subtropical/tropical regions. Since the outbreak of the 
2009 influenza pandemic, the A(H3N2) and A(H1N1)
pdm09 subtypes have become the two major influenza 
virus strains, along with influenza B viruses that cause 
the disease in humans. The emergence of A(H1N1)
pdm09 prompts a better evaluation of the genetic char-
acteristics of influenza viruses and improvement of the 
surveillance of circulating influenza viruses resistance 
to existing antiviral drugs. The A(H3N2) subtype has 
circulated and caused influenza in human populations 
before the emergence of A(H1N1)pdm09 subtype. Anti-
viral drugs constitute an important tool to control these 
infections. The neuraminidase inhibitors (NAIs) oselta-
mivir and zanamivir have been the cornerstone of anti-
influenza therapy in recent years. However, their effec-
tiveness has been compromised by rapid emergence of 
resistance among some A(H3N2) and A(H1N1) viruses 
circulating in different geographic regions (Okomo-Ad-
hiambo et al. 2010). One of the most frequent changes 
in A(H3N2) viruses during or soon after oseltamivir 
administration has been reported to be the amino acid 
substitution of glutamic acid (E) to valine (V) at position 
119 of neuraminidase (NA) (Eshaghi et al. 2014). A re-
cent study, based on the experiments on viruses collect-
ed via the Global Influenza Surveillance and Response 
System (GISRS) and analysed by five World Health Or-
ganization Collaborating Centres (WHO CCs) between 
May 2014 and May 2015, demonstrated that from a total 
of 13,312 viruses examined, approximately 0.5% (n = 
68) showed highly reduced inhibition by at least one of 
the four NAIs tested and another 56 isolates exhibited 
moderately reduced inhibition (Hurt et al. 2016).
An immunocompromised host is a patient who does 
not have the ability to respond normally to an infection 
due to weakened immune system. This inability to fight 
infection makes these patients susceptible to bacterial, 
fungal, and viral infections, such as influenza (Eshaghi 
et al. 2014). Antiviral prophylaxis and therapy are partic-
ularly important in these patients because the influenza 
vaccine is often poorly immunogenic and unlikely to be 
fully protective (Yousuf et al. 1997). In addition, these 
patients are at risk of developing antiviral resistance and 
subsequent complications. It is worth pointing out that 
although there is a stable low rate of oseltamivir and 
zanamivir resistance among circulating influenza A vi-
ruses, a higher prevalence of drug-resistant influenza vi-
ruses in severely immunosuppressed or immunocompro-
mised patients undergoing antiviral treatment has been 
well documented (Abed et al. 2009, Memoli et al. 2010). 
A(H3N2) viruses showing oseltamivir resistance due to 
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the E119V NA mutation have previously been detected 
in immunocompromised paediatric patients undergoing 
oseltamivir treatment. Antiviral therapy in immunocom-
promised patients is often associated with prolonged viral 
shedding (Ruiz-Carrascoso et al. 2010). In some cases, the 
E119V oseltamivir-resistant variants were selected within 
a few days of oseltamivir treatment, whereas in other 
cases, many weeks of cumulative treatment were under-
taken before the E119V variant was detected (Hurt et al. 
2013). Mixed viral populations that contained sensitive 
and resistant viruses in different proportions have also 
been detected in intra-treatment samples collected from 
paediatric patients (Valinotto et al. 2010).
In this report, we describe the emergence of the 
E119V substitution in the NA protein of an influenza 
A(H3N2) isolate detected in a clinical specimen collect-
ed from an immunocompromised patient after oseltami-
vir treatment in Argentina during 2014 epidemic season.
MATERIALS AND METHODS
Patients and data collection - Weekly influenza sur-
veillance is routinely conducted by the Respiratory Vi-
ruses Laboratory at the National Institute of Infectious 
Diseases, National Agency of Laboratories, and Insti-
tutes of Health (ANLIS) Dr Carlos G Malbrán, a WHO 
National Influenza Centre (NIC), through its National 
Influenza and Respiratory Virus Surveillance Network 
(NIRN). This Network, which comprises 65 laborato-
ries distributed all over the country, usually processes 
respiratory samples such as swabs and nasopharyngeal 
aspirates (NPA), and examines them by immunofluo-
rescence methods using commercial kits for detection 
of the respiratory syncytial virus, adenovirus, parainflu-
enza virus 1-3, influenza A and B viruses. Besides, some 
laboratories (n = 35) carry out influenza virus detection 
by quantitative reverse transcriptase polymerase chain 
reaction (qRT-PCR) using specific primers and probes 
recommended by Centres for Disease Control and Pre-
vention (CDC). All influenza A and B clinical specimens 
detected by the NIRN are routinely submitted to the NIC 
located in Buenos Aires for isolation and further antigen-
ic and genomic characterisation. All the results obtained 
are compiled by the Ministry of Health in the national 
database called SIVILA (National System of Laboratory 
Surveillance). Clinical data [regarding influenza-like ill-
ness (ILI) and pneumonia] are also collected by the Na-
tional System of Health Surveillance. These data come 
from clinical notifications that public and private hospi-
tals communicate to the Ministry of Health.
Viral RNA and subtyping - Extraction of total nucleic 
acid from clinical specimens was performed at the NIC 
using the QIAamp® Viral RNA Mini Kit (QIAGEN), ac-
cording to the manufacturer’s instructions. Influenza A 
virus subtypes H3 and H1pdm09 were identified by qRT-
PCR using a SuperScript III Platinum One-Step qRT-PCR 
system (Invitrogen), specific primers, and FAM-BHQ1 
dual-labelled probes developed by CDC (Shu et al. 2011).
Molecular antiviral assays - In 2014, a rapid genotypic 
screening was implemented at the NIC to identify the sin-
gle nucleotide polymorphism (SNP) encoding E119V sub-
stitution in clinical specimens that contained A(H3N2) 
influenza virus. This technique allows the differentiation 
between wild-type (WT) and oseltamivir-resistant vi-
ruses. The original protocol was provided by Dr Adam 
Meijer, National Institute for Public Health and the Envi-
ronment, The Netherlands. It was essentially a qRT-PCR 
assay conducted using a reaction mixture that included 
specific primers for influenza A(H3N2) NA segment 
with the E119V coding region and a pair of dual-labelled 
probes for the detection of the E119 and V119 variants.
Sanger sequencing and phylogenetic analysis - The 
NA segment (1-1052 bp) of the viruses from pre- and post-
treatment samples was sequenced to confirm the results 
obtained by E119V SNP screening. The haemagglutinin 
(HA) segment of the E119V variant was also sequenced 
(1-986 bp). The sequencing PCR amplicons were purified 
with the MinElute® Gel Extraction Kit (QIAGEN). Se-
quencing reactions were performed using the BigDye® 
Terminator v3.1 Cycle Sequencing Kit (Applied Bio-
systems™), and the products were analysed on an ABI 
PRISM® 3700 Genetic Analyser (Applied Biosystems™).
Sequencing reaction conditions and primer sequenc-
es are available on request.
Sequences were analysed using BioEdit software, 
version 7.0.5.3 (http://www.mbio.ncsu.edu/BioEdit/
bioedit.html). MEGA 4 (Tamura et al. 2007) and 
MEGA 5 (Tamura et al. 2011) programmes were used 
to build the phylogenetic trees using the neighbour-
joining distance method. Tree topology was supported 
by bootstrap analysis with 1000 replicates. Vaccine 
strain sequences, as well as sequences from viruses 
collected in other countries, were obtained from the 
EpiFlu database available via the Global Initiative on 
Sharing All Influenza Data (GISAID) website, https://
www.gisaid.org, and included in the analysis.
Ethics - Written informed consent and explicit ethical 
approval were not sought because this was an observational 
study undertaken as part of the routine virological surveil-
lance (anonymously, without identification of the patients). 
This procedure is indicated in the Terms of Reference for 
WHO NICs, which describe the basis of the WHO surveil-
lance in more than 130 countries (Pontoriero et al. 2011).
RESULTS
In 2014, the NIRN analysed a total of 51,744 samples 
for the detection of respiratory virus isolates that came 
from paediatric and adult inpatients and outpatients with 
acute lower and upper respiratory tract infections. The 
samples were accompanied by the clinic-epidemiological 
forms containing at least some basic information, such as 
patient initials, gender, age, city/state of onset of illness 
and the dates of the initiation of the symptoms and sample 
collection. Of these, 1,679 (3.24%) samples tested posi-
tive for influenza virus. This year, from these samples, 
the NIC received a total of 1,140 influenza virus isolates 
positive clinical specimens. The mean age of donors was 
43 years (range: one month to 92 years); 54% of donors 
were men. Out of these influenza samples received at the 
NIC, 888 (78%) contained A(H3N2) virus, 244 (21.3%) 
had influenza type B viruses, and 8 (0.7%) were positive 
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for A(H1N1)pdm09. In 2014, influenza viruses circulated 
all year round in Argentina, and their main activity was 
observed from June to December. The total number of 
influenza viruses detected and ILI cases registered, by 
epidemiological week (EW) in 2014, is detailed in Fig. 1. 
The A(H3N2) virus was first detected in May and pro-
gressively became the most frequent influenza A subtype 
circulating in Argentina. A(H3N2) activity was regis-
tered in the period from June to September 2014 (EW 23-
EW 37), with a peak in EW 29 and subsequent decrease 
in frequency to a very low level until the end of the year. 
Influenza A(H1N1)pdm09 virus co-circulated at a fre-
quency much lower than that of the A(H3N2) and influ-
enza B viruses. The first peak of ILI cases registered in 
EW 27 perfectly matched the surge in A(H3N2) activity. 
Meanwhile, the second peak in EW 34 was related to the 
co-circulation of influenza A and B viruses.
Out of 888 A(H3N2) samples received at the NIC, 842 
were tested for the E119V substitution: 836 samples were 
collected from untreated patients and six samples were 
obtained from six patients (four of them immunocompro-
mised) after treatment. WT E119 genotype was found in 
841 specimens and one sample contained a mixture of 
viral E119/V119 subpopulations. This sample came from 
a post-treatment specimen collected from an immuno-
compromised patient. The sample was sent to the NIC 
by an NIRN laboratory member located in Tucuman, 
a province in the north of the country. Data collected 
showed that this specimen was from a 12-year-old girl 
with a history of acute B-cell lymphoblastic leukaemia. 
On September 15th, the first NPA tested positive for 
influenza A virus by qRT-PCR analysis carried out in 
Tucuman, and oseltamivir therapy (75 mg twice a day 
orally) was administered from that date until September 
20th. On September 25th, the second NPA of the same 
patient also tested positive for influenza A virus. First 
and second samples were sent to the NIC. Unfortunately, 
none of these viruses could be recovered in tissue culture 
and phenotypic studies could not be performed. Sanger 
sequencing of both pre- and post-treatment samples 
confirmed the results obtained by E119V SNP screen-
ing and further quantitative assays will be necessary to 
confirm this finding (Fig. 2). Nucleotide sequences of all 
the genes sequenced have been deposited in the GISAID 
database under accession numbers EPI_ISL_172694 and 
EPI_ISL_172636. The HA sequence analysis of the resis-
tant virus demonstrated that this strain belongs to group 
3C.3 and is different from the A(H3N2) strain included in 
the 2014 influenza vaccine (McCauley et al. 2015).
DISCUSSION
Although the frequency of the E119V substitution is 
low (0.01%) (WHO 2015), in this study, we have been 
able to detect a mixture of E119/V119 subpopulations 
in an influenza A(H3N2) virus isolate recovered from 
a post-treatment immunocompromised patient. This 
variant had been observed previously by other research-
ers (Hurt et al. 2013, Eshaghi et al. 2014). Because the 
resistant variant was not recovered in tissue culture, 
phenotypic assays could not be performed. Molecular 
detection of the E119V SNP cannot alone inform about 
oseltamivir resistance without complementary studies 
to confirm the decrease of the susceptibility to antiviral 
drugs. Based on published data, the clinical impact of 
this polymorphism is not clear, but it may depend on the 
proportion of the drug-resistant (V119) variant (WHO 
2015). However, following the recommendation of the 
WHO working group on the surveillance of influenza 
antiviral susceptibility, any detection of V119 variant is 
critical to the evolution of the patients and should result 
in a prompt treatment review (WHO 2015).
The absence of the E119V change in the pre-treat-
ment sample suggests that the V119 variant arose as a 
consequence of the oseltamivir therapy. This finding is 
in agreement with previous reports about the emergence 
of E119V substitution in oseltamivir-treated immuno-
Fig. 1: total number of influenza viruses and influenza-like illness cases detected in Argentina in 2014. Data are presented by epidemiological week.
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compromised patients infected with influenza A(H3N2) 
virus (Ison et al. 2006). The risk of developing resistance 
during antiviral treatment is considerably higher in the 
immunocompromised patients than in immunocompe-
tent ones (Hurt et al. 2012). Because of this, samples for 
NAIs testing should be taken specially from the immu-
nocompromised patient undergoing influenza treatment. 
These samples should be analysed immediately using 
molecular-based techniques for common resistance-as-
sociated mutations [e.g., E119V in A(H3N2) and H275Y 
in A(H1N1)pdm09 viruses], and prompt feedback must 
be given to treating clinicians, so that alternative thera-
pies can be initiated (Hurt et al. 2013). The implemen-
tation of a rapid molecular technique for the detection 
of known substitutions, that confer antiviral resistance 
using reagents and equipment available at the NIC, rep-
resents a valuable tool for antiviral susceptibility moni-
toring, especially for testing pre- and post-treatment in-
fluenza positive clinical specimens.
This first study represents the beginning of the Na-
tional systematic surveillance of the antiviral suscepti-
bility of circulating influenza A(H3N2) viruses in Ar-
gentina that will contribute to better decisions in health 
Fig. 2: (A) a quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) amplification plot corresponding to the wild-type E119 vi-
rus; (B) a qRT-PCR amplification plot corresponding to the mixture of E119 and V119 viral subpopulations; (C) a Sanger sequencing chromato-
gram showing base substitutions in the codon for residue 119 of the neuraminidase gene in the pre-treatment sample; and (D) Sanger sequencing 
chromatogram of the post-treatment sample; sensitive/resistant E119E/V subpopulations.
policies and help in selecting optimal medical treatment. 
Within the frame of the WHO Global Influenza Surveil-
lance, the NICs have the responsibility for early detec-
tion of variants associated with antiviral resistance in in-
dividual patients, and cluster populations that may have 
implications on public health. The national data gener-
ated and analysed in this study may help improve the 
knowledge about the resistance of influenza viruses to 
antiviral drugs, which is a global concern.
ACKNOWLEDGEMENTS
To the NIRN laboratories, for the submission of clinical 
samples along with the clinical information about the patients, 
the Tissue Culture Laboratory at INEI, ANLIS Dr Carlos G 
Malbrán, for supplying the cells and media routinely used by the 
NIC, and Mr Carlos Vargas, for his network of logistic assistance
REFERENCES
Abed Y, Baz M, Boivin G. A novel neuraminidase deletion muta-
tion conferring resistance to oseltamivir in clinical influenza A/
H3N2 virus. J Infect Dis. 2009; 199(2): 180-3.
Eshaghi A, Shalhoub S, Rosenfeld P, Li A, Higgins R, Stogios P, et al. 
Multiple influenza A (H3N2) mutations conferring resistance to 
5Mem Inst Oswaldo Cruz, Rio de Janeiro, 2016
neuraminidase inhibitors in a bone marrow transplant recipient. 
Antimicrob Agents Chemother. 2014; 58(12): 7188-97.
Hurt A, Besselaar T, Daniels R, Ermetal B, Fry A, Gubareva L, et al. 
Global update on the susceptibility of human influenza viruses 
to neuraminidase inhibitors, 2014-2015. Antiviral Res. 2016; 
132: 178-85.
Hurt A, Chotpitayasunondh T, Cox N, Daniels R, Fry A, Gubareva 
L, et al. Antiviral resistance during the 2009 influenza A H1N1 
pandemic: public health, laboratory, and clinical perspectives. 
Lancet Infect Dis. 2012; 12(3): 240-8.
Hurt A, Leang S, Tiedemann K, Butler J, Mechinaud F, Kelso A, et 
al. Progressive emergence of an oseltamivir-resistant A(H3N2) 
virus over two courses of oseltamivir treatment in an immuno-
compromised paediatric patient. Influenza Other Respir Viruses. 
2013; 7(6): 904-8.
Ison M, Gubareva L, Atmar R, Treanor J, Hayden F. Recovery of 
drug-resistant influenza virus from immunocompromised pa-
tients: a case series. J Infect Dis. 2006; 193(6): 760-4.
McCauley J, Daniels R, Lin Y, Xiang Z, Gregory V, Whittaker L, et 
al. Report prepared for the WHO annual consultation on the com-
position of influenza vaccine for the Northern Hemisphere 2015-
16. WHO Influenza Centre London. 2015. Available from: https://
www.crick.ac.uk/media/221813/nimr-report-feb2015-web.pdf.
Memoli M, Hrabal R, Hassantoufighi A, Jagger B, Sheng Z, Eichel-
berger M, et al. Rapid selection of a transmissible multidrug-re-
sistant influenza A/H3N2 virus in an immunocompromised host. 
J Infect Dis. 2010; 201(9): 1397-403.
Okomo-Adhiambo M, Demmler-Harrison G, Deyde V, Sheu T, Xu 
X, Klimov A, et al. Detection of E119V and E119I mutations in 
influenza A (H3N2) viruses isolated from an immunocompro-
mised patient: challenges in diagnosis of oseltamivir resistance. 
Antimicrob Agents Chemother. 2010; 54(5):1834-1841.
Pontoriero A, Baumeister E, Campos A, Savy V. Virological surveil-
lance and antiviral resistance of human influenza virus in Argen-
tina, 2005-2008. Rev Panam Salud Publica. 2011; 30(6): 634-40.
Ruiz-Carrascoso G, Casas I, Pozo F, Gonzalez-Vincent M, Perez-
Brena P. Prolonged shedding of amantadine- and oseltamivir-
resistant influenza A(H3N2) virus with dual mutations in an 
immunocompromised infant. Antivir Ther. 2010; 15(7): 1059-63.
Shu B, Wu K, Emery S, Villanueva J, Johnson R, Guthrie E, et al. De-
sign and performance of the CDC real-time reverse transcriptase 
PCR swine flu panel for detection of 2009 A (H1N1) pandemic 
influenza virus. J Clin Microbiol. 2011; 49(7): 2614-19.
Tamura K, Dudley J, Nei M, Kumar S. MEGA 4: molecular evolu-
tionary genetics analysis (MEGA) software version 4.0. Mol Biol 
Evol. 2007; 24(8): 1596-9.
Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 
MEGA 5: molecular evolutionary genetics analysis using maxi-
mum likelihood, evolutionary distance, and maximum parsimo-
ny methods. Mol Biol Evol. 2011; 28(10): 2731-9.
Valinotto L, Diez R, Barrero P, Farias J, Lopez E, Mistchenko A. Emer-
gence of intratreatment resistance to oseltamivir in pandemic in-
fluenza A H1N1 2009 virus. Antivir Ther. 2010; 15(6): 923-7.
WHO - World Health Organization. Global Influenza Surveillance and 
Response System working group on surveillance of influenza anti-
viral susceptibility. Wkly Epidemiol Rec. 2015; 90(33): 414-9.
Yousuf H, Englund J, Couch R, Rolston K, Luna M, Goodrich J, et al. 
Influenza among hospitalized adults with leukemia. Clin Infect 
Dis. 1997; 24(6): 1095-9.
